Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0022-5347(17)63367-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Soluble guanylate cyclase stimulators and activators as potential antihypertensive drugs.
Hypertens Res
January 2025
Department of Pathological and Molecular Pharmacology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
Poor blood pressure control in treated patients with hypertension is an important topic in the field of hypertension, and an unmet need for new therapeutic drugs remains. Soluble guanylate cyclase (sGC), a key signal transduction enzyme responsible for vasodilation, has attracted increasing interest as a therapeutic target in various cardiovascular diseases. Two different sGC agonists, sGC stimulators and activators, can increase its enzymatic activity in reduced and oxidized/apo forms, respectively.
View Article and Find Full Text PDFUnravelling a mystery of hypokalemic hypertension- a rare case report of a reninoma.
BMC Endocr Disord
December 2024
National Hospital of Sri Lanka, Colombo, Sri Lanka.
Background: Reninoma is a rare cause of secondary hypertension, which can be cured with surgery if identified early before any target organ damage occurs. It leads to hypokalaemia and hypertension and typically responds well to treatment with renin-angiotensin-aldosterone system blockers. However, confirmation of the diagnosis and the localisation of this rare culprit lesion can be challenging.
View Article and Find Full Text PDFRenovascular hypertension following by juxtaglomerular cell tumor: a challenging case with 12-year history of resistant hypertension and hypokalemia.
BMC Endocr Disord
November 2024
Department of Endocrinology and metabolism, Guangzhou Red Cross Hospital of Jinan University, No. 396, Tong Fu Zhong Rd, Guangzhou, 510220, China.
Background: Adolescents with secondary hyperaldosteronism often present with severe and treatment-resistant hypertension, along with hypokalemia. Renovascular hypertension is frequently caused by renal artery stenosis, primarily due to atherosclerosis and fibromuscular dysplasia (FMD). The presence of an accessory renal artery (ARA) is a common anatomical variation that can contribute to secondary renal vascular hypertension.
View Article and Find Full Text PDFVascular Abnormalities and Neurofibromatosis Type 1: A Paediatric Case Series.
J Child Neurol
January 2025
Pediatric Clinic, "Microcitemico - A. Cao" Pediatric Hospital, University of Cagliari, Cagliari, Italy.
Article Synopsis
- - Neurofibromatosis type 1 (NF1) is a genetic disorder caused by a mutation that leads to issues like vascular and neurological abnormalities.
- - Serious complications can include moyamoya syndrome, which causes the progressive narrowing of brain arteries, and renal artery stenosis, a common cause of high blood pressure in NF1 patients.
- - The article reviews clinical cases of NF1 vasculopathy, focusing on diagnosis, management, and potential future strategies for screening and treatment options.
Severe hypertension in tuberous sclerosis complex caused by renal artery stenosis: A case report.
Nephrology (Carlton)
December 2024
Hemangioma and Vascular Anomaly Center, Capital Institute of Pediatrics, Beijing, China.
Article Synopsis
- - Tuberous sclerosis complex (TSC) is a rare genetic condition that can lead to various complications, including arterial hypertension caused by renal cysts or angiomyolipomas.
- - A case study highlights a boy with TSC who faced severe hypertension despite being on five anti-hypertensive medications; he was found to have left renal artery stenosis (RAS).
- - Following treatment with percutaneous transluminal renal angioplasty (PTRA), the boy's blood pressure normalized over a year and a half, suggesting the importance of screening TSC patients for RAS that may be treatable.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!